论文部分内容阅读
目的通过测定 ＨＢｅＡｇ阳性慢性肝炎（ＣＨＢ）血清 ＨＢＶ－ ＤＮＡ水平，判断干扰素在病情治疗中的作用。方法 ２８例ＨＢｅＡｇ阳性 ＣＨＢ接受干扰素治疗。血清 ＨＢＶ－ ＤＮＡ浓度测定应用 ＡＣ－９６００ Ａｍｐｌｉｓｅｎｓｏｒ荧光 ＰＣＲ定量系统，测定范围定为１０３００－９５０ｃｏｐｉｅｓ／ｍＬ。结果 ２８例 ＨＢｅＡｇ阳性 ＣＨＢ患者治疗结束时呈完全应答（ＣＲ）者 １３例，无应答（ＮＲ）１５例。对 １３例 ＣＲ患者继续随访６个月，其中４例血清ＡＬＴ再升高（复燃）。血清ＨＢＶ－ＤＮＡ水平在治疗前，ＣＲ不伴ＡＬＴ复燃组、ＣＲ伴ＡＬＴ复燃组和ＮＲ组之间无差异；治疗结束时，ＣＲ不伴 ＡＬＴ复燃组 ＨＢＶ－ ＤＮＡ为 １０３４４ ０４３ｃｏｐｉｅｓ／ｍＬ，明显低于 ＣＲ伴 ＡＬＴ复燃组（１０６８４ ０５１ｃｏｐｉｅｓ／ｍＬ）和ＮＲ组（１０７１８ ０６６ｃｏｐｉｅｓ／ｍＬ）。结论在ＨＢｅＡｇ阳性ＣＨＢ病例，干扰素治疗结束时，检测ＨＢＶ－ＤＮＡ水平对于判断疗效有指导价值，ＨＢＶ－ ＤＮＡ低于 １０４ｃｏｐｉｅｓ／ｍＬ往往能取得持久疗效。
Objective To determine the role of interferon in the treatment of disease by measuring the level of serum HBV DNA in HBeAg-positive chronic hepatitis (CHB). Methods 28 cases of HBeAg-positive CHB were treated with interferon. Serum HBV DNA concentration determination using AC-9600 Amplisensor fluorescence PCR quantitative system, the determination of the range of 10300-950copies / mL. Results Thirty-eight patients with HBeAg-positive CHB had complete response (CR) at the end of treatment and 15 without response (NR). Thirteen patients with CR were followed up for 6 months. Serum ALT increased again in 4 patients (resurgence). Serum HBV-DNA levels before treatment, CR with ALT flaming group, CR with ALT flare group and no difference between the NR group; the end of treatment, CR without ALT flare HBV-DNA was 10344 043copies / mL , Significantly lower than CR with ALT re-ignite group (10684 051copies / mL) and NR group (10718 066copies / mL). Conclusion HBeAg positive CHB cases, the end of interferon treatment, the detection of HBV-DNA levels for the evaluation of therapeutic effect, HBV-DNA less than 104copies / mL often can achieve lasting efficacy.